# Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration

> **NCT00712491** · PHASE1,PHASE2 · TERMINATED · sponsor: **Santen Inc.** · enrollment: 20 (actual)

## Conditions studied

- Age-related Macular Degeneration
- Choroidal Neovascularization

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT00712491
- **Lead sponsor:** Santen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2009-11
- **Final completion:** 2010-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2013-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00712491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00712491, "Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00712491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*